Mathematical modelling of autoimmune myocarditis and the effects of immune checkpoint inhibitors by van der Vegt, S, Polonchuk, L, Wang, K, Waters, SL, Baker, RE

Rapid characterisation of hERG channel kinetics I: using an automated high-throughput system by Lei, CL, Clerx, M, Gavaghan, D, Polonchuk, L, Mirams, GR, Wang, K

A model informed approach to assess the risk of checkpoint inhibitors induced myocarditis by ven der Vegt, S, Wang, Y, Polonchuk, L, Wang, K, Waters, S, Baker, RE

Hierarchical Bayesian modelling of variability and uncertainty in synthetic action potential traces by Johnstone, R, Bardenet, R, Gavaghan, D, Polonchuk, L, Davies, M, Mirams, G

Importance of modelling hERG binding in predicting drug-induced action potential prolongations for drug safety assessment by Farm, HJ, Clerx, M, Cooper, F, Polonchuk, L, Wang, K, Gavaghan, DJ, Lei, CL

Models of the cardiac L-type calcium current: a quantitative review by Agrawal, A, Wang, K, Polonchuk, L, Cooper, J, Hendrix, M, Gavaghan, DJ, Mirams, GR, Clerx, M

A parameter representing missing charge should be considered when calibrating action potential models by Barral, Y-SHM, Shuttleworth, JG, Clerx, M, Whittaker, DG, Wang, K, Polonchuk, L, Gavaghan, DJ, Mirams, GR

Rapid characterisation of hERG channel kinetics II: temperature dependence by Lei, CL, Clerx, M, Beattie, KA, Melgari, D, Hancox, JC, Gavaghan, DJ, Polonchuk, L, Wang, K, Mirams, GR

Recent developments in using mechanistic cardiac modelling for drug safety evaluation by Mirams, G, Noble, D, Davies, M, Wang, K, Caruso, A, Walz, A, Lave, T, Schuler, F, Singer, T, Polonchuk, L

Tailoring mathematical models to stem-cell derived cardiomyocyte lines can improve predictions of drug-induced changes to their electrophysiology by Lei, C, Wang, K, Clerx, M, Johnstone, R, Hortigon-Vinagre, M, Zamora, V, Allan, A, Smith, G, Gavaghan, D, Mirams, G, Polonchuk, L